11:50 AM EST - Cardiome Pharma Corp. : and Merck said that Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA has recommended marketing approval for BRINAVESS or vernakalant for conversion of recent onset atrial fibrillation. Granting of marketing authorization by the European Commission is expected later this year and will apply to 27 countries. Cardiome Pharma Corp.
shares T.COM are trading down $0.04 at $8.94.
